Search results
Hace 3 días · Based on short-term price targets offered by nine analysts, the average price target for AbCellera Biologics Inc. comes to $15.78. The forecasts range from a low of $8.00 to a high of $28.00. The ...
Hace 5 días · ABCL. Revenue: Reported at $10.0 million, down from $12.2 million in Q1 2023, falling short of the estimated $10.84 million. Net Loss: Recorded a net loss of $40.6 million, slightly below above ...
Hace 4 días · AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems.
Hace 4 días · ABCL is an independent entity and such information from any ABCL Affiliate are not in any manner intended or to be construed as being endorsed by ABCL or Facilities Provider. The information does not constitute investment or financial advice or advice to buy or sell, or to endorse or solicitation to buy or sell any securities or other financial instrument for any reason whatsoever.
Hace 1 día · A number of other equities analysts have also commented on ABCL. KeyCorp cut their price target on AbCellera Biologics from $8.00 to $7.00 and set an “overweight” rating for the company in a ...
Hace 1 día · AbCellera Biologics Inc. - Hold. Zacks' proprietary data indicates that AbCellera Biologics Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the ABCL shares ...
Hace 5 días · Srinivasa Raju Chintalapati or Srini Raju, as he is known as, owns the network of Television stations called TV9 through the Associated Broadcasting Company Private Limited. He is an investor advisor with focus in the areas of Technology, Health and Wellness, Media and Entertainment, among many others. Throughout his career, Srini Raju has been ...
